It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Immunity to previously encountered viruses can alter response to unrelated pathogens. We reasoned that similar mechanism may also involve SARS-CoV-2 and thereby affect the specificity and the quality of the immune response against the virus. Here, we employed high-throughput next generation phage display method to explore the link between antibody immune response to previously encountered antigens and spike (S) glycoprotein. By profiling the antibody response in COVID-19 naïve individuals with a diverse clinical history (including cardiovascular, neurological, or oncological diseases), we identified 15 highly antigenic epitopes on spike protein that showed cross-reactivity with antigens of seasonal, persistent, latent or chronic infections from common human viruses. We observed varying degrees of cross-reactivity of different viral antigens with S in an epitope-specific manner. The data show that pre-existing SARS-CoV-2 S1 and S2 cross-reactive serum antibody is readily detectable in pre-pandemic cohort. In the severe COVID-19 cases, we found differential antibody response to the 15 defined antigenic and cross-reactive epitopes on spike. We also noted that despite the high mutation rates of Omicron (B.1.1.529) variants of SARS-CoV-2, some of the epitopes overlapped with the described mutations. Finally, we propose that the resolved epitopes on spike if targeted by re-called antibody response from SARS-CoV-2 infections or vaccinations can function in chronically ill COVID-19 naïve/unvaccinated individuals as immunogenic targets to boost antibodies augmenting the chronic conditions. Understanding the relationships between prior antigen exposure at the antibody epitope level and the immune response to subsequent infections with viruses from a different strain is paramount to guiding strategies to exit the COVID-19 pandemic.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Protobios LLC, Tallinn, Estonia (GRID:grid.455035.2); Tallinn University of Technology, Department of Chemistry and Biotechnology, Tallinn, Estonia (GRID:grid.6988.f) (ISNI:0000000110107715)
2 Protobios LLC, Tallinn, Estonia (GRID:grid.455035.2)
3 Protobios LLC, Tallinn, Estonia (GRID:grid.455035.2); Tallinn University of Technology, Department of Chemistry and Biotechnology, Tallinn, Estonia (GRID:grid.6988.f) (ISNI:0000000110107715); DXLabs LLC, Tallinn, Estonia (GRID:grid.6988.f)
4 Tallinn University of Technology, Department of Chemistry and Biotechnology, Tallinn, Estonia (GRID:grid.6988.f) (ISNI:0000000110107715)
5 North Estonia Medical Centre Foundation, Tallinn, Estonia (GRID:grid.454953.a) (ISNI:0000 0004 0631 377X)
6 University of Tartu, Institute of Clinical Medicine, Psychiatry Clinic of Tartu University Hospital, Tartu, Estonia (GRID:grid.10939.32) (ISNI:0000 0001 0943 7661)
7 University of Tartu, Department of Physiology, Institute of Biomedicine and Translational Medicine, Tartu, Estonia (GRID:grid.10939.32) (ISNI:0000 0001 0943 7661); University of Tartu, Center of Excellence for Genomics and Translational Medicine, Tartu, Estonia (GRID:grid.10939.32) (ISNI:0000 0001 0943 7661)
8 University of Liege, Dental Biomaterial Research Unit (d-BRU), Faculty of Medicine, Liege, Belgium (GRID:grid.4861.b) (ISNI:0000 0001 0805 7253)
9 University of Liege, Department of Periodontology and Oral Surgery, Faculty of Medicine, Liege, Belgium (GRID:grid.4861.b) (ISNI:0000 0001 0805 7253)
10 Helsinki University Hospital, Department of Anaesthesiology, Intensive Care and Pain Medicine, Helsinki, Finland (GRID:grid.15485.3d) (ISNI:0000 0000 9950 5666); University of Helsinki, SleepWell Research Programme, Department of Pharmacology, Helsinki, Finland (GRID:grid.7737.4) (ISNI:0000 0004 0410 2071)
11 University of Helsinki, Oral and Maxillofacial Diseases, Helsinki University Hospital, Helsinki, Finland (GRID:grid.7737.4) (ISNI:0000 0004 0410 2071)
12 University of Helsinki, Translational Immunology Research Program, Department of Neurology, Neurocenter, Helsinki University Hospital, Helsinki, Finland (GRID:grid.7737.4) (ISNI:0000 0004 0410 2071)
13 University of Helsinki, Department of Virology, Medicum, Helsinki, Finland (GRID:grid.7737.4) (ISNI:0000 0004 0410 2071)
14 University of Helsinki, Department of Biochemistry and Developmental Biology, Faculty of Medicine, Helsinki, Finland (GRID:grid.7737.4) (ISNI:0000 0004 0410 2071); Minerva Foundation Institute for Medical Research, Helsinki, Finland (GRID:grid.452540.2)
15 University of Nottingham, Immunology and Immuno-Bioengineering Group, School of Life Science, Faculty of Medicine and Health Sciences, Nottingham, United Kingdom (GRID:grid.4563.4) (ISNI:0000 0004 1936 8868)




